

### COMPLETE

Collector: BCH website (Website Survey)
Started: Tuesday, February 11, 2014 7:11:18 AM
Last Modified: Wednesday, February 12, 2014 6:36:02 AM

Time Spent: 23:24:43

PAGE 1

| Q1: Type of submission: | Party |
|-------------------------|-------|
| Q1: Type of submission: | raity |

### PAGE 2

| Q2: Name of the Party:                                                                                                                                                                                                    | Syrian Arab Republic                                                          |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Q3: Person submitting this questionnaire:                                                                                                                                                                                 |                                                                               |
| Full Name:                                                                                                                                                                                                                | Belal Alhayek                                                                 |
| Email Address:                                                                                                                                                                                                            | bilalalhayk@yahoo.com                                                         |
| Q4: Institution(s) or organization(s) that participated in the testing:                                                                                                                                                   | Government authority(ies)                                                     |
| Q5: Context in which the testing was conducted                                                                                                                                                                            | Group event(s) (e.g., w orkshop, training course, meeting)                    |
|                                                                                                                                                                                                                           |                                                                               |
| Records (e.g. http://bch.cbd.int/database/record.shtml?docu<br>http://bch.cbd.int/database/record.shtml?documentid=104905                                                                                                 | mentid=104904 and<br>i) or other publicly accessible web pages containing the |
| Q6: Actual case(s) of risk assessment used in the testing: No Records (e.g. http://bch.cbd.int/database/record.shtml?documentid=104905 technical and scientific data of the actual cases of risk asses Risk Assessment 1: | mentid=104904 and<br>i) or other publicly accessible web pages containing the |

| 8: Name of the other Government:                                                                                                                                                                                                                                                                                                                                                                                | Respondent skipped this question |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|
| 99: Person submitting this questionnaire:                                                                                                                                                                                                                                                                                                                                                                       | Respondent skipped this question |
| Q10: Institution(s) or organization(s) that participated in the esting:                                                                                                                                                                                                                                                                                                                                         | Respondent skipped this question |
| Q11: Context in which the testing was conducted                                                                                                                                                                                                                                                                                                                                                                 | Respondent skipped this question |
| Q12: Actual case(s) of risk assessment used in the testing: Note: Please enter the hyperlinks of BCH Risk Assessment Records (e.g. http://bch.cbd.int/database/record.shtml? documentid=104904 and http://bch.cbd.int/database/record.shtml? documentid=104905) or other publicly accessible web pages containing the technical and scientific data of the actual cases of risk assessment used in the testing. | Respondent skipped this question |
| Q13: In what language was the Guidance tested?                                                                                                                                                                                                                                                                                                                                                                  | Respondent skipped this question |

### PAGE 4

| Q14: Name of the organization:                                                                                                                                                                                                                                                                                                                                                                                  | Respondent skipped this question |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|
| Q15: Person submitting this questionnaire:                                                                                                                                                                                                                                                                                                                                                                      | Respondent skipped this question |
| Q16: Institution(s) or organization(s) that participated in the testing:                                                                                                                                                                                                                                                                                                                                        | Respondent skipped this question |
| Q17: Context in which the testing was conducted                                                                                                                                                                                                                                                                                                                                                                 | Respondent skipped this question |
| Q18: Actual case(s) of risk assessment used in the testing: Note: Please enter the hyperlinks of BCH Risk Assessment Records (e.g. http://bch.cbd.int/database/record.shtml? documentid=104904 and http://bch.cbd.int/database/record.shtml? documentid=104905) or other publicly accessible web pages containing the technical and scientific data of the actual cases of risk assessment used in the testing. | Respondent skipped this question |
| Q19: In what language was the Guidance tested?                                                                                                                                                                                                                                                                                                                                                                  | Respondent skipped this question |

### PAGE 5

Q20: Would you like to submit an evaluation of the following section of the Guidance: Part I: The Roadmap for Risk Assessment

Yes

| Q21: This section of the Guidance is practical.1                                                                                                                                                 |                                  |  |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|--|
| (no label)                                                                                                                                                                                       | Strongly Agree                   |  |
| Q22: Would you like to suggest improvements to this section to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made:                  | Respondent skipped this question |  |
| Q23: This section of the Guidance is useful or has utility.2                                                                                                                                     |                                  |  |
| (no label)                                                                                                                                                                                       | Strongly Agree                   |  |
| Q24: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made:            | Respondent skipped this question |  |
| Q25: This section of the Guidance is consistent with the Cartag                                                                                                                                  | ena Protocol on Biosafety.3      |  |
| (no label)                                                                                                                                                                                       | Strongly Agree                   |  |
| Q26: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made: | Respondent skipped this question |  |

| o label)                                                                                                                                                                                                                       | Strongly Agree                   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|
| 110 14001)                                                                                                                                                                                                                     | Cuongly Agroo                    |
| Q28: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made: | Respondent skipped this question |
| Q29: Here you may provide further details to explain your answers in evaluating this section of the Guidance:                                                                                                                  | Respondent skipped this question |

### PAGE 7

Q30: Would you like to submit an evaluation of the following section of the Guidance: Part II: Specific types of LMOs or Traits - Risk assessment of LMOs with stacked genes or traits

Yes

| no label)                                                                                                                                                                                                                                                                   | Strongly Agree                                                                    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Q32: Would you like to suggest improvements to this section to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made:                                                                                             | Respondent skipped this question                                                  |
| Q33: This section of the Guidance is useful or has utility.2                                                                                                                                                                                                                |                                                                                   |
| (no label)                                                                                                                                                                                                                                                                  | Strongly Agree                                                                    |
| Q34: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made:                                                                                       | Respondent skipped this question                                                  |
|                                                                                                                                                                                                                                                                             |                                                                                   |
| Q35: This section of the Guidance is consistent with the Carta                                                                                                                                                                                                              | gena Protocol on Biosafety.3                                                      |
| Q35: This section of the Guidance is consistent with the Cartagonic (no label)                                                                                                                                                                                              | gena Protocol on Biosafety.3 Strongly Agree                                       |
|                                                                                                                                                                                                                                                                             | •                                                                                 |
| (no label)  Q36: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made:                                                                | Strongly Agree  Respondent skipped this question                                  |
| (no label)  Q36: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements                                                                               | Strongly Agree  Respondent skipped this question                                  |
| (no label)  Q36: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made:  Q37: This section of the Guidance takes into account past and | Strongly Agree  Respondent skipped this question  present experiences with LMOs.4 |

Q40: Would you like to submit an evaluation of the following section of the Guidance: Part II: Specific types of LMOs or Traits - Risk assessment of LM crops with tolerance to abiotic stress

Yes

### PAGE 10

| Q41: This section of the Guidance is practical.1 (no label)                                                                                                                                                                    | Strongly Agree                   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|
| Q42: Would you like to suggest improvements to this section to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made:                                                | Respondent skipped this question |
| Q43: This section of the Guidance is useful or has utility.2                                                                                                                                                                   |                                  |
| (no label)                                                                                                                                                                                                                     | Strongly Agree                   |
| Q44: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made:                                          | Respondent skipped this question |
| Q45: This section of the Guidance is consistent with the Cartag                                                                                                                                                                | gena Protocol on Biosafety.3     |
| (no label)                                                                                                                                                                                                                     | Strongly Agree                   |
| Q46: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made:                               | Respondent skipped this question |
| Q47: This section of the Guidance takes into account past and p                                                                                                                                                                | present experiences with LMOs.4  |
| (no label)                                                                                                                                                                                                                     | Strongly Agree                   |
| Q48: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made: | Respondent skipped this question |
|                                                                                                                                                                                                                                |                                  |
| Q49: Here you may provide further details to explain your answers in evaluating this section of the Guidance:                                                                                                                  | Respondent skipped this question |

### PAGE 11

 ${\tt Q50:}$  Would you like to submit an evaluation of the following section of the Guidance: Part II: Specific types of LMOs or Traits - Risk assessment of LM mosquitoes

Yes

| Q51: This section of the Guidance is prac | cical.1        |
|-------------------------------------------|----------------|
| (no label)                                | Strongly Agree |
|                                           |                |

Q52: Would you like to suggest improvements to this section Respondent skipped this question to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made: Q53: This section of the Guidance is useful or has utility.2 (no label) Strongly Agree Respondent skipped this question Q54: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made: Q55: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.3 (no label) Strongly Agree Respondent skipped this question Q56: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made: Q57: This section of the Guidance takes into account past and present experiences with LMOs.4 (no label) Strongly Agree

Q58: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made:

Q59: Here you may provide further details to explain your answers in evaluating this section of the Guidance:

Respondent skipped this question

### PAGE 13

Q60: Would you like to submit an evaluation of the following section of the Guidance: Part II: Specific types of LMOs or Traits - Risk assessment of LM trees

Yes

### PAGE 14

# Q61: This section of the Guidance is practical.1 (no label) Q62: Would you like to suggest improvements to this section to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made: Q63: This section of the Guidance is useful or has utility.2 (no label) Strongly Agree Q64: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made:

| no label)                                                                                                                                                                                        | Strongly Agree                   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|
| Q66: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made: | Respondent skipped this question |
|                                                                                                                                                                                                  |                                  |
| Q67: This section of the Guidance takes into account past and լ                                                                                                                                  | present experiences with LMOs.4  |
| Q67: This section of the Guidance takes into account past and p<br>(no label)                                                                                                                    | Strongly Agree                   |
|                                                                                                                                                                                                  | •                                |

### PAGE 15

Q70: Would you like to submit an evaluation of the following section of the Guidance: Part III: Monitoring of LMOs Released into the Environment

Yes

| •                                                                                                                                                                                               |                                  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|
| no label)                                                                                                                                                                                       | Strongly Agree                   |
| Q72: Would you like to suggest improvements to this section o increase its practicality? If so, please indicate the line numbers and explain which improvements could be made:                  | Respondent skipped this question |
| 273: This section of the Guidance is useful or has utility.2                                                                                                                                    |                                  |
| no label)                                                                                                                                                                                       | Strongly Agree                   |
| Q74: Would you like to suggest improvements to this section o increase its usefulness/utility? If so, please indicate the ine numbers and explain which improvements could be nade:             | Respondent skipped this question |
| Q75: This section of the Guidance is consistent with the Cartag                                                                                                                                 | ena Protocol on Biosafety.3      |
| no label)                                                                                                                                                                                       | Strongly Agree                   |
| Q76: Would you like to suggest improvements to this section o increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made: | Respondent skipped this question |
| 277: This section of the Guidance takes into account past and p                                                                                                                                 | present experiences with LMOs.4  |
| no label)                                                                                                                                                                                       | Strongly Agree                   |

Q78: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made:

Q79: Here you may provide further details to explain your answers in evaluating this section of the Guidance:

Respondent skipped this question

**PAGE 17** 

Q80: Would you like to submit an evaluation of the following section of the Guidance: Background Documents

Yes

### PAGE 18

| Q81: This section of the Guidance is practical.1   |                                               |
|----------------------------------------------------|-----------------------------------------------|
| (no label)                                         | Strongly Agree                                |
| Q82: This section of the Guidance is useful or has | s utility.2                                   |
| (no label)                                         | Strongly Agree                                |
| Q83: This section of the Guidance is consistent w  | vith the Cartagena Protocol on Biosafety.3    |
| (no label)                                         | Strongly Agree                                |
| Q84: This section of the Guidance takes into acco  | ount past and present experiences with LMOs.4 |
| (no label)                                         | Strongly Agree                                |

### PAGE 19

Q85: Please use the space below if you wish to provide additional feedback regarding the testing of the Guidance on Risk Assessment of Living Modified Organisms:

Respondent skipped this question